A deep dive into the safety profile, FDA regulatory actions, and clinical evidence for NMN and NR supplements, including known adverse signals, banned-ingredient rulings, and what the data actually show.
A guide to NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) injection technique, pharmacology, dosing, and the clinical trial data behind NAD+ precursor therapy.
A clinical deep-dive into how NMN and NR raise NAD+ levels, influence mitochondrial function, insulin sensitivity, and whole-body energy expenditure, with primary-literature citations and dosing guidance.
A clinician-level review of NMN and NR (nicotinamide mononucleotide and nicotinamide riboside) supplementation after bariatric surgery, covering absorption, dosing, metabolic rationale, and current evidence.
Evidence-based protocol for resuming nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) supplementation after acute illness, with dosing guidance, timing, contraindications, and the latest trial data.
Enclomiphene is off-label for male hypogonadism, approved only for infertility under IND. Trials show 75-90% reach testosterone above 300 ng/dL.
A guide to using copper tripeptide GHK-Cu for hair growth off-label, covering the evidence base, dosing protocols, and monitoring requirements.
Is metformin a longevity drug? We review the biology, clinical trial data from TAME and beyond, GRADE evidence levels, off-label status, and what prescribers and patients need to know before considering metformin for aging.
Metformin is FDA-approved for type 2 diabetes but is used off-label for weight maintenance. Learn what the clinical evidence shows, who may benefit, and how dosing is typically structured.
Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, but physicians prescribe it off-label for weight loss. Learn what the SURMOUNT trials showed, how dosing works, and what to expect.
Ozempic kidney protection: the approved use in type 2 diabetes and CKD, FLOW trial results, weekly dosing, monitoring and evidence beyond diabetes.
A deep dive into using semaglutide (Ozempic 0.5 to 2.0 mg) off-label for polycystic ovary syndrome. Covers the clinical evidence, GRADE ratings, FDA approval context, dosing, risks, and when to consider Wegovy or metformin instead.
A clinical evidence summary of liraglutide 3 mg (Saxenda) used off-label for nonalcoholic steatohepatitis (NASH), covering trial data, mechanisms, dosing, and guideline positions.
A clinical evidence summary of semaglutide 2.4 mg (Wegovy) for cardiovascular prevention, covering SELECT trial data, FDA-approved indications, off-label context, and GRADE-level evidence ratings.
Zepbound (tirzepatide) is FDA-approved for obesity, not diabetes, that role belongs to Mounjaro. Here is what the clinical trial data show, how physicians approach off-label prescribing, and what patients should know before starting.
Zepbound (tirzepatide) is FDA-approved for obesity, not diabetes. This evidence summary covers the clinical trial data, off-label prescribing rationale, and how it compares to Mounjaro for blood-sugar control.
Everything clinicians and families need to know about monitoring oral low-dose minoxidil in adolescents aged 12 to 17, including blood pressure, fluid retention, lab schedules, and growth-velocity considerations.
A clinical guide to Cigna coverage, prior authorization, formulary tier, step therapy, and appeal strategies for oral minoxidil for hair loss.
Low-dose oral minoxidil runs about $15 to $50 a month compounded, versus $10 to $20 for generic finasteride. See how the costs and effects compare.
A clinician-level review of oral minoxidil's mechanism of action, current low-dose evidence, and the emerging pipeline of topical-oral hybrid, controlled-release, and sex-specific formulations in development for androgenetic alopecia.
A guide to Kaiser Permanente's formulary status, prior-authorization criteria, step-therapy requirements, and appeal process for oral minoxidil used to treat androgenetic alopecia.
A deep dive into the oral minoxidil patent history, generic availability, compounding status, mechanism of action, and low-dose dosing evidence for androgenetic alopecia.
Evidence-based guide to oral minoxidil dosing in children under 12, covering FDA labeling, weight-based calculations, safety monitoring, and published trial data for pediatric hair loss conditions.
A complete clinical guide to monitoring young adults aged 18 to 29 on low-dose oral minoxidil for hair loss, covering baseline labs, cardiovascular checks, fluid retention, fertility considerations, and visit schedules.
A clinician-level review of oral low-dose minoxidil for hair loss in patients with autoimmune conditions, covering drug interactions, immune effects, cardiovascular monitoring, and prescribing guidance.
A clinical review of oral minoxidil's hepatic safety profile, covering pharmacokinetics, monitoring protocols, and what low-dose data mean for patients using it off-label for hair loss.
Evidence-based guide to stopping oral minoxidil before surgery, covering the pharmacology behind the hold window, cardiovascular risks, anesthesia interactions, and when to restart dosing post-operatively.
A physician-level review of oral minoxidil's effects on kidney function, including renal hemodynamics, fluid retention, when low-dose use is safe, and what monitoring your prescriber should order.
A deep-dive into how low-dose oral minoxidil affects sexual function, libido, and erectile health. Covers trial data, mechanisms, risk stratification, and clinical guidance for patients considering oral minoxidil for hair loss.
A guide to stopping Ozempic (semaglutide 0.5 to 2.0 mg) safely, covering tapering strategies, rebound risks, glycemic monitoring, and what to expect after your last dose.
FDA-approved March 2024 for adults with established cardiovascular disease and BMI 27+. SELECT trial showed 20% MACE reduction (N=17,604) vs placebo over 3.3 years.
Can Ozempic (semaglutide 0.5 to 2.0 mg) help with menopause-related weight gain? Review the trial evidence, dosing schedule, side effects, and how clinicians combine it with HRT.
A guide to using semaglutide (Ozempic) for metabolic syndrome, covering trial evidence, off-label dosing, cardiovascular outcomes, and what to expect week by week.
A guide to using semaglutide (Ozempic) for NAFLD and MASLD, covering trial evidence, off-label dosing, liver-fat outcomes, and how it compares to resmetirom.
Can semaglutide (Ozempic) treat obstructive sleep apnea? A look at what the weight-loss trial evidence does and does not show, how Ozempic differs from Wegovy and the FDA-approved OSA drug Zepbound, and what questions remain unanswered.
A guide to using semaglutide (Ozempic) for prediabetes, covering clinical trial evidence, off-label dosing protocols, side effects, and insurance considerations.
A clinician-level guide to the complete Ozempic (semaglutide 0.5 to 2.0 mg) monitoring schedule: which labs to order, when to order them, what targets to aim for, and which exams cannot be skipped.
A breakdown of Ozempic (semaglutide 0.5 to 2.0 mg) regulatory approvals across the US, EU, Canada, and UK, including approval dates, indications, dose limits, and the evidence base behind each authorization.
An evidence-based guide to using semaglutide 0.5 to 2.0 mg (Ozempic) in transplant recipients, people living with HIV, CKD, hepatic impairment, older adults, and other complex populations. Includes mechanism, dosing considerations, drug interactions, and what the trial evidence does and does not show.
A clinical deep-dive into semaglutide 0.5 to 2.0 mg and kidney outcomes: FLOW, SUSTAIN-7, LEADER-extension data, GFR trajectories, dosing in CKD, and when Ozempic genuinely protects versus when caution applies.
A breakdown of AOD-9604's legal status in Louisiana, covering FDA classification, 503A/503B compounding rules, the Louisiana Board of Pharmacy, and how patients can legally access the peptide.
A guide to AOD-9604's federal and Maryland-specific legal status, including FDA scheduling, 503A/503B compounding rules, and how to get a legitimate prescription.
A guide to AOD-9604's federal and Oregon-specific legal status, covering FDA bulk-drug lists, 503A/503B compounding, state pharmacy board rules, and how to obtain a legitimate prescription.
BPC-157 occupies a gray area under federal law and California state regulations. This guide explains the FDA bulk-drug status, 503A/503B compounding rules, and the only legal access paths available to California residents in 2025.
A guide to BPC-157's federal regulatory status, Colorado-specific pharmacy law, and the legal paths a Colorado resident can use to obtain it under current 2024 to 2025 rules.
A guide to the legal status of BPC-157 in Michigan, covering FDA scheduling, 503A/503B compounding rules, the Michigan Board of Pharmacy, and how patients can legally access this peptide.
A breakdown of CJC-1295's legal status in Colorado, covering FDA compounding rules, state pharmacy board regulations, and how patients can legally access this growth hormone secretagogue.
A guide to the federal and Florida-state legal framework governing CJC-1295, including FDA compounding rules, 503A/503B pharmacy pathways, and how to get a lawful prescription.
A detailed look at PT-141 (bremelanotide) legal status in Arizona, covering FDA approval, federal scheduling, 503A/503B compounding rules, state pharmacy board regulations, and how Arizona residents can legally obtain a prescription.
A guide to the federal and Colorado-specific legal framework for PT-141 (Bremelanotide), including FDA approval status, 503A/503B compounding rules, and how to get a valid prescription.
A guide to the federal and Illinois-specific legal framework governing PT-141 (Bremelanotide), including FDA approval status, 503A/503B compounding rules, and how Illinois residents can obtain a lawful prescription.
A guide to the federal and Kentucky-specific legal status of PT-141 (Bremelanotide), how to obtain a valid prescription, and what compounding pharmacy rules apply in 2025.
A guide to the federal and Louisiana-specific legal framework for PT-141 (Bremelanotide), including FDA approval status, 503A/503B compounding rules, and how to get a valid prescription.
A guide to the federal and Minnesota-specific legal framework for PT-141 (Bremelanotide), including FDA approval status, compounding rules, and how to get a valid prescription.
A guide to the federal and Missouri-specific legal framework for PT-141 (Bremelanotide), including FDA approval status, 503A/503B compounding rules, and how to get a legitimate prescription.
A guide to the federal and Ohio-specific legal status of PT-141 (Bremelanotide), how prescriptions work, what compounding pharmacies can legally dispense, and how Ohio residents can access FDA-approved bremelanotide.
Sermorelin is legal in Illinois when prescribed by a licensed physician and dispensed by a compliant compounding pharmacy. Learn the federal and state rules, how to get a prescription, and what to expect from treatment.
A complete guide to the legal status of sermorelin in Oregon, covering federal FDA rules, 503A/503B compounding, Oregon state pharmacy board requirements, and how to get a legal prescription.
A guide to Sermorelin's legal status in Texas, covering federal FDA rules, 503A/503B compounding pharmacy law, state medical board requirements, and how to get a valid prescription.
A guide to Sermorelin's legal status in Virginia, covering federal FDA rules, 503A/503B compounding law, state pharmacy board requirements, and how to get a legitimate prescription.